44 related articles for article (PubMed ID: 9431839)
1. Neurophysiological contributors to advantageous risk-taking: an experimental psychopharmacological investigation.
MacCormack JK; Armstrong-Carter E; Humphreys KL; Muscatell KA
Soc Cogn Affect Neurosci; 2021 Sep; 16(9):926-936. PubMed ID: 33860790
[TBL] [Abstract][Full Text] [Related]
2. [Mechanism of action of zolmitriptan].
Pascual J
Neurologia; 1998 Oct; 13 Suppl 2():9-15. PubMed ID: 9859690
[TBL] [Abstract][Full Text] [Related]
3. Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol.
Tsai M; Case M; Ardayfio P; Hochstetler H; Wilbraham D
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):629-638. PubMed ID: 31950732
[TBL] [Abstract][Full Text] [Related]
4. Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.
Reboredo M; Chang HC; Barbero R; Rodríguez-Ortigosa CM; Pérez-Vizcaíno F; Morán A; García M; Banales JM; Carreño N; Alegre F; Herrero I; Quiroga J; Prieto J; Sangro B
PLoS One; 2013; 8(1):e52683. PubMed ID: 23341903
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine.
McEnroe JD; Fleishaker JC
Clin Pharmacokinet; 2005; 44(3):237-46. PubMed ID: 15762767
[TBL] [Abstract][Full Text] [Related]
6. Clinically significant drug interactions with agents specific for migraine attacks.
Eadie MJ
CNS Drugs; 2001; 15(2):105-18. PubMed ID: 11460889
[TBL] [Abstract][Full Text] [Related]
7. Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.
Goldberg MR; Sciberras D; De Smet M; Lowry R; Tomasko L; Lee Y; Olah TV; Zhao J; Vyas KP; Halpin R; Kari PH; James I
Br J Clin Pharmacol; 2001 Jul; 52(1):69-76. PubMed ID: 11453892
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.
Jhee SS; Shiovitz T; Crawford AW; Cutler NR
Clin Pharmacokinet; 2001; 40(3):189-205. PubMed ID: 11327198
[TBL] [Abstract][Full Text] [Related]
9. Drug information incorrect.
Duckmanton L
Can Fam Physician; 2000 Apr; 46():780, 783. PubMed ID: 10790808
[No Abstract] [Full Text] [Related]
10. Zolmitriptan: a review of its use in migraine.
Spencer CM; Gunasekara NS; Hills C
Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025
[TBL] [Abstract][Full Text] [Related]
11. Zolmitriptan.
Can Fam Physician; 1999 Jun; 45():1491-4, 1497-501. PubMed ID: 10386213
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
Dixon R; Gillotin C; Gibbens M; Posner J; Peck RW
Br J Clin Pharmacol; 1997 Mar; 43(3):273-81. PubMed ID: 9088582
[TBL] [Abstract][Full Text] [Related]
13. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
Peck RW; Seaber EJ; Dixon RM; Layton GR; Weatherley BC; Jackson SH; Rolan PE; Posner J
Clin Pharmacol Ther; 1998 Mar; 63(3):342-53. PubMed ID: 9542478
[TBL] [Abstract][Full Text] [Related]
14. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
Seaber E; On N; Dixon RM; Gibbens M; Leavens WJ; Liptrot J; Chittick G; Posner J; Rolan PE; Pack RW
Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
[TBL] [Abstract][Full Text] [Related]
15. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
Rolan P
Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
Martin GR
Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
[TBL] [Abstract][Full Text] [Related]
17. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
Peck RW; Seaber EJ; Dixon R; Gillotin CG; Weatherley BC; Layton G; Posner J
Br J Clin Pharmacol; 1997 Dec; 44(6):595-9. PubMed ID: 9431839
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
